Antipodes Global SMID Active ETF (ASX:MIDS)
Broader universe. Greater opportunity
Small and mid-capitalisation companies represent a vast and diverse opportunity set, with over 7,000 companies across more than 40 countries. Despite many of these companies being leaders in their country or industry, far fewer industry experts track these businesses compared to larger, more familiar names.
This creates a greater opportunity set to exploit mispricing and uncover value.
How do we invest?
At Antipodes, we start with the industry, not the stock.
Our industry-led research approach identifies change that is taking place, whether that is cyclical, structural or socio-macroeconomic in nature. Starting with the industry layer builds a deep understanding of the industry leaders, helping us assess the competitive edge of smaller participants. This process enables us to uncover genuine long-term winners while avoiding those vulnerable to disruption.
With over 30 investment professionals, Antipodes brings institutional scale to a part of the market typically served by niche stock pickers. This breadth enables us to identify differentiated opportunities across industries and geographies – from emerging disruptors to established mid-cap leaders.
The result: an award-winning Global SMID fund that hunts for the best opportunities across the value chain in every industry, building a portfolio designed to capture upside while protecting the downside.
Capital preservation mindset
A long-only strategy with Antipodes' pragmatic value approach and characteristic focus on risk management and capital protection with a goal of delivering strong risk adjusted returns relative to the MSCI ACWI SMID index.
Portfolio diversification
Provides exposure beyond Australian equities and global large capitalisation equities through a high-conviction small – mid capitalisation portfolio (min 30 stocks).
Broaden global style and index exposure
Small-mid capitalisation companies are often under-researched compared to large caps, creating opportunities for active managers to uncover and exploit mispricing.
Delivering strong risk-adjusted returns
Past performance is not a reliable indicator of future performance. Risk metrics are based on gross of fee returns in AUD since inception.
Note: Since inception, for every 1% increase in the ACWI SMID index, Antipodes Global SMID Active ETF has risen 1.4% (upside capture). Conversely, for every 1% decline in the index, the Fund has fallen just 0.46%.
Performance
All returns are net of fees and in AUD terms. Past performance is not a reliable indicator of future performance.
1 The inception date of the Antipodes Global SMID Fund is 2 November 2022.
2 MSCI All Country World SMID Cap Net Index (AUD).
Learn more
The Antipodes Global SMID Fund has been rated “Recommended” by Zenith Investment Partners and “Investment Grade” by Lonsec Research.
- BT Panorama
- HUB24
- Mason Stevens
- Netwealth
- Praemium (IDPS only)
Important information
This page is prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) as the investment manager of the Antipodes Global SMID Fund Active ETF (ARSN 654 913 309) (the ‘Fund’). Pinnacle Fund Services Limited (‘PFSL’) (ABN 29 082 494 362, AFSL 238371) is the product issuer of the Fund and is a wholly owned subsidiary of Pinnacle Investment Management Group Limited (‘Pinnacle’) (ABN 22 100 325 184). PFSL is not licensed to provide financial product advice.
The information contained in this page is general information only and does not take into account your objectives, financial situation or needs. Before making a decision to acquire, or continue to hold units in, the Fund, you should consider the Product Disclosure Statement (PDS) and Target Market Determination (TMD). For historic TMDs, please contact Pinnacle Client Services via phone 1300 010 311 or email service@pinnacleinvestment.com. Any persons relying on this information should obtain professional advice before doing so and consider the appropriateness of the information having regard to your specific circumstances.
Past performance is not a reliable indicator of future performance and the repayment of capital is not guaranteed. The specific risks associated with investing in the Fund, and the risks associated with the Fund’s investments, are discussed in Section 3 of the PDS. Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information available as at the date of publication and may later change without notice.
Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Fund. There can be no assurance that the Fund will achieve its investment objectives. The value of your units at any point in time may be worth less than your original investment even after taking into account the reinvestment of Fund distributions. Returns are not guaranteed, and you may lose some or all of your money. The specific risks associated with investing in the Fund, and the risks associated with the Fund’s investments, are discussed in Section 3 of the Product Disclosure Statement. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this website. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.
The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (Antipodes Global SMID Fund Active ETF assigned February 2025) referred to in this piece is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.
Zenith Investment Partners Pty Ltd ABN 27 103 132 672 AFSL 226872 Fund Awards issued 23 October 2025 are solely statements of opinion and not a recommendation in relation to making any investment decisions. Fund Awards are current for 12 months and subject to change at any time. Fund Awards for previous years are for historical purposes only. Full details on Zenith Fund Awards at www.zenithpartners.com.au/zenith-fund-awards-2025.
The rating issued 04/2025 for the Antipodes Global SMID Fund Active ETF is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2025 Lonsec. All rights reserved.